A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 232 participants.

Also called NCT06649110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 232 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06649110
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Czechia, France, Germany, Greece, Italy, Latvia, Mexico, Poland, Portugal, Romania, Serbia, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06649110. Randomized; double masking; primary purpose treatment. Start 2024-10-24 (actual); primary completion 2028-11-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Condition
Healthy Volunteers, Pulmonary Arterial Hypertension
Intervention (Drug)
LTP
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06649110
Content hash
3da417d8ea1af1dabde08b69c03f4cc952a8ee2c6c9d8129dc27ba0750126236